• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于检测tau蛋白病变的[(18)F]AV-1451(T807)的人体辐射剂量测定

Human Radiation Dosimetry of [(18)F]AV-1451(T807) to Detect Tau Pathology.

作者信息

Choi Jae Yong, Lyoo Chul Hyoung, Lee Jae Hoon, Cho Hanna, Kim Kyeong Min, Kim Jin Su, Ryu Young Hoon

机构信息

Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.

Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.

出版信息

Mol Imaging Biol. 2016 Aug;18(4):479-82. doi: 10.1007/s11307-015-0924-7.

DOI:10.1007/s11307-015-0924-7
PMID:26728162
Abstract

PURPOSE

[(18)F]AV-1451 is a positron emission tomography (PET) radioligand for detecting paired helical filament tau. Our aim was to estimate the radiation dose of [(18)F]AV-1451 in humans.

PROCEDURES

Whole-body PET scans were acquired for six healthy volunteers (three male, three female) for 128 min after injection of [(18)F]AV-1451 (268 ± 31 MBq). Radiation doses were estimated using the OLINDA/EXM software.

RESULTS

The estimated organ doses ranged from 7.81 to 81.2 μSv/MBq. The critical organ for radiation burden was the liver. Radiation doses to the reproductive and blood-forming organs were 14.15, 8.43, and 18.35 μSv/MBq for the ovaries, testes, and red marrow, respectively. The mean effective dose was 22.47 ± 3.59 μSv/MBq.

CONCLUSIONS

A standard single injection of 185 MBq (5 mCi) results in an effective dose of 4.7 mSv in a healthy subject. Therefore, [(18)F]AV-1451 could be used in multiple PET scans of the same subject per year.

摘要

目的

[18F]AV - 1451是一种用于检测配对螺旋丝tau的正电子发射断层扫描(PET)放射性配体。我们的目的是估算[18F]AV - 1451在人体中的辐射剂量。

程序

对6名健康志愿者(3名男性,3名女性)注射[18F]AV - 1451(268±31MBq)后进行128分钟的全身PET扫描。使用OLINDA/EXM软件估算辐射剂量。

结果

估算的器官剂量范围为7.81至81.2μSv/MBq。辐射负担的关键器官是肝脏。卵巢、睾丸和红骨髓的生殖和造血器官辐射剂量分别为14.15、8.43和18.35μSv/MBq。平均有效剂量为22.47±3.59μSv/MBq。

结论

标准单次注射185MBq(5mCi)在健康受试者中产生的有效剂量为4.7mSv。因此,[18F]AV - 1451可用于同一受试者每年的多次PET扫描。

相似文献

1
Human Radiation Dosimetry of [(18)F]AV-1451(T807) to Detect Tau Pathology.用于检测tau蛋白病变的[(18)F]AV-1451(T807)的人体辐射剂量测定
Mol Imaging Biol. 2016 Aug;18(4):479-82. doi: 10.1007/s11307-015-0924-7.
2
Biodistribution and Radiation Dosimetry of [F]Mefway in Humans.[F]美芬妥英在人体中的生物分布与辐射剂量测定
Mol Imaging Biol. 2016 Dec;18(6):803-806. doi: 10.1007/s11307-016-0955-8.
3
Biodistribution and Radiation Dosimetry for the Tau Tracer F-THK-5351 in Healthy Human Subjects.健康人体受试者中Tau示踪剂F-THK-5351的生物分布与辐射剂量测定
J Nucl Med. 2017 Sep;58(9):1498-1503. doi: 10.2967/jnumed.116.189126. Epub 2017 Mar 23.
4
Biodistribution and Radiation Dosimetry for the Novel SV2A Radiotracer [(18)F]UCB-H: First-in-Human Study.新型SV2A放射性示踪剂[(18)F]UCB-H的生物分布与辐射剂量测定:首例人体研究
Mol Imaging Biol. 2015 Aug;17(4):557-64. doi: 10.1007/s11307-014-0820-6.
5
Human Radiation Dosimetry for the N-Methyl-D-Aspartate Receptor Radioligand 11C-CNS5161.N-甲基-D-天冬氨酸受体放射性配体11C-CNS5161的人体辐射剂量测定
J Nucl Med. 2015 Jun;56(6):869-72. doi: 10.2967/jnumed.114.152447. Epub 2015 Apr 30.
6
Biodistribution and radiation dosimetry of 18F-CP-18, a potential apoptosis imaging agent, as determined from PET/CT scans in healthy volunteers.18F-CP-18(一种潜在的细胞凋亡显像剂)在健康志愿者中的 PET/CT 扫描的生物分布和辐射剂量学。
J Nucl Med. 2013 Dec;54(12):2087-92. doi: 10.2967/jnumed.113.119800. Epub 2013 Oct 17.
7
Biodistribution and Radiation Dosimetry of the Enterobacteriaceae-Specific Imaging Probe [(18)F]Fluorodeoxysorbitol Determined by PET/CT in Healthy Human Volunteers.通过PET/CT在健康人体志愿者中测定肠杆菌科特异性成像探针[(18)F]氟脱氧山梨醇的生物分布和辐射剂量学
Mol Imaging Biol. 2016 Oct;18(5):782-7. doi: 10.1007/s11307-016-0946-9.
8
F-FPYBF-2, a new F-18 labelled amyloid imaging PET tracer: biodistribution and radiation dosimetry assessment of first-in-man F-FPYBF-2 PET imaging.F-FPYBF-2,一种新型的F-18标记淀粉样蛋白成像PET示踪剂:首例人体F-FPYBF-2 PET成像的生物分布和辐射剂量学评估
Ann Nucl Med. 2018 May;32(4):256-263. doi: 10.1007/s12149-018-1240-5. Epub 2018 Feb 16.
9
Preclinical Safety Evaluation and Human Dosimetry of [F]MK-6240, a Novel PET Tracer for Imaging Neurofibrillary Tangles.用于成像神经纤维缠结的新型正电子发射断层扫描示踪剂 [F]MK-6240 的临床前安全性评价和人体剂量学。
Mol Imaging Biol. 2020 Feb;22(1):173-180. doi: 10.1007/s11307-019-01367-w.
10
Biodistribution, Tumor Detection, and Radiation Dosimetry of F-5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine in Solid Tumors.固体肿瘤中 F-5-氟-2'-脱氧胞苷与四氢尿苷的生物分布、肿瘤检测和辐射剂量学
J Nucl Med. 2019 Apr;60(4):492-496. doi: 10.2967/jnumed.118.216994. Epub 2018 Nov 2.

引用本文的文献

1
Human biodistribution and radiation dosimetry of two novel α-synuclein PET tracers, F-SPAL-T-06 and F-C05-05.两种新型α-突触核蛋白PET示踪剂F-SPAL-T-06和F-C05-05的人体生物分布和辐射剂量测定
Sci Rep. 2025 Mar 13;15(1):8640. doi: 10.1038/s41598-025-93520-5.
2
Human biodistribution and radiation dosimetry for the tau tracer [F]Florzolotau in healthy subjects.健康受试者中tau示踪剂[F]Florzolotau的人体生物分布和辐射剂量测定。
EJNMMI Radiopharm Chem. 2024 Apr 2;9(1):27. doi: 10.1186/s41181-024-00259-x.
3
Radiation dosimetry and pharmacokinetics of the tau PET tracer florzolotau (18F) in healthy Japanese subjects.

本文引用的文献

1
Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue.在尸检脑组织上验证新型tau正电子发射断层显像示踪剂[F-18]-AV-1451(T807)
Ann Neurol. 2015 Nov;78(5):787-800. doi: 10.1002/ana.24517. Epub 2015 Sep 25.
2
Imaging biomarkers in tauopathies.tau蛋白病中的影像学生物标志物。
Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S26-8. doi: 10.1016/j.parkreldis.2015.08.011. Epub 2015 Aug 14.
3
Preclinical Evaluation of [(18)F]THK-5105 Enantiomers: Effects of Chirality on Its Effectiveness as a Tau Imaging Radiotracer.
在健康的日本受试者中,tau PET 示踪剂 florzolotau(18F)的辐射剂量学和药代动力学。
Ann Nucl Med. 2023 May;37(5):300-309. doi: 10.1007/s12149-023-01828-x. Epub 2023 Mar 9.
4
Dosimetry and efficacy of a tau PET tracer [F]MK-6240 in Japanese healthy elderly and patients with Alzheimer's disease.tau PET 示踪剂[F]MK-6240 在日本健康老年人群体和阿尔茨海默病患者中的剂量学和疗效。
Ann Nucl Med. 2023 Feb;37(2):108-120. doi: 10.1007/s12149-022-01808-7. Epub 2022 Nov 21.
5
Biodistribution and Dosimetry Evaluation for a Novel Tau Tracer [F]-S16 in Healthy Volunteers and Its Application in Assessment of Tau Pathology in Alzheimer's Disease.新型Tau示踪剂[F]-S16在健康志愿者中的生物分布和剂量学评估及其在阿尔茨海默病Tau病理学评估中的应用
Front Bioeng Biotechnol. 2022 Feb 10;9:812818. doi: 10.3389/fbioe.2021.812818. eCollection 2021.
6
A Brief History of Nuclear Medicine Physics, Instrumentation, and Data Sciences in Korea.韩国核医学物理、仪器与数据科学简史
Nucl Med Mol Imaging. 2021 Dec;55(6):265-284. doi: 10.1007/s13139-021-00721-7. Epub 2021 Nov 12.
7
Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer's Disease.Tauvid™:首款获美国食品药品监督管理局批准用于阿尔茨海默病中tau蛋白病理成像的正电子发射断层显像(PET)示踪剂。
Pharmaceuticals (Basel). 2021 Jan 30;14(2):110. doi: 10.3390/ph14020110.
8
Use of 55 PET radiotracers under approval of a Radioactive Drug Research Committee (RDRC).在放射性药物研究委员会(RDRC)批准下使用55种正电子发射断层扫描(PET)放射性示踪剂。
EJNMMI Radiopharm Chem. 2020 Nov 11;5(1):24. doi: 10.1186/s41181-020-00110-z.
9
An one-pot two-step automated synthesis of [18F]T807 injection, its biodistribution in mice and monkeys, and a preliminary study in humans.[18F]T807 注射液的一锅两步自动化合成、在小鼠和猴子中的生物分布,以及在人体中的初步研究。
PLoS One. 2019 Jul 1;14(7):e0217384. doi: 10.1371/journal.pone.0217384. eCollection 2019.
10
Preclinical Safety Evaluation and Human Dosimetry of [F]MK-6240, a Novel PET Tracer for Imaging Neurofibrillary Tangles.用于成像神经纤维缠结的新型正电子发射断层扫描示踪剂 [F]MK-6240 的临床前安全性评价和人体剂量学。
Mol Imaging Biol. 2020 Feb;22(1):173-180. doi: 10.1007/s11307-019-01367-w.
[(18)F]THK - 5105对映体的临床前评估:手性对其作为tau成像放射性示踪剂有效性的影响
Mol Imaging Biol. 2016 Apr;18(2):258-66. doi: 10.1007/s11307-015-0879-8.
4
[(18)F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease.[(18)F]THK-5117 PET 用于评估阿尔茨海默病中的神经纤维缠结病理。
Eur J Nucl Med Mol Imaging. 2015 Jun;42(7):1052-61. doi: 10.1007/s00259-015-3035-4. Epub 2015 Mar 20.
5
Developments in Tau PET Imaging.Tau正电子发射断层显像(PET)成像的进展
Can J Neurol Sci. 2014 Sep;41(5):547-53. doi: 10.1017/cjn.2014.15.
6
A concise radiosynthesis of the tau radiopharmaceutical, [(18) F]T807.tau放射性药物[(18)F]T807的简洁放射性合成。
J Labelled Comp Radiopharm. 2013 Dec;56(14):736-40. doi: 10.1002/jlcr.3098. Epub 2013 Jul 24.
7
Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls.tau 病小鼠模型和阿尔茨海默病患者与正常对照的 tau 病理学成像比较。
Neuron. 2013 Sep 18;79(6):1094-108. doi: 10.1016/j.neuron.2013.07.037.
8
Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808.新型 PHF-tau 放射性配体 [F18]-T808 的早期临床 PET 成像结果。
J Alzheimers Dis. 2014;38(1):171-84. doi: 10.3233/JAD-130098.
9
Suggested pathway to assess radiation safety of ¹⁸F-labeled PET tracers for first-in-human studies.评估用于人体首次研究的¹⁸F标记PET示踪剂辐射安全性的建议途径。
Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1781-3. doi: 10.1007/s00259-013-2512-x. Epub 2013 Jul 19.
10
[(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease.[18F]T807,一种新型用于阿尔茨海默病的tau 正电子发射断层扫描成像剂。
Alzheimers Dement. 2013 Nov;9(6):666-76. doi: 10.1016/j.jalz.2012.11.008. Epub 2013 Feb 12.